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The Increasing Incidence of Fusariosis
The fungal genus Fusarium contains an extraordinary genetic diversity and is globally distrib-
uted in plants, soil, water, and manmade habitats. Plant-pathogenic members of the genus
cause diseases in many agriculturally important crops, with billions of dollars of economical
losses annually. Their presence as food contaminants is detrimental because of production of
biologically active, highly toxic secondary metabolites.
Remarkably, human fusariosis does not have a long history. This is in contrast to comparable
opportunistic pathogens like Scedosporium spp., which have been known since the 19th century.
The first case of human Fusarium infection was reported only in 1958 and concerned an eye
infection caused by a blow from a cow tail [1]. Fusarium causes a very wide spectrum of diseases,
ranging frommildly superficial to fatally disseminated [2]. During the initial years, most reported
infections were caused by traumatic inoculation. Keratitis is still the most common infection by
Fusarium species, occurring especially in the warmer climates of India, China, and Brazil [3].
After 1960, the increasing use of antibiotics became a major predisposing condition [4]. Since
1970, prolonged neutropenia due to intensified cytotoxic treatment of hematologic malignancies
was the leading risk factor in novel types of fusariosis [5]. Since 1980, Fusarium infections have
been seen in severely immunocompromised patients with a 100%mortality rate, e.g., in cases of
cerebral involvement [6]. Today, invasive surgery, organ transplantation, chronic steroid treat-
ment, and aggressive cytotoxic therapy are the main risk factors of fusariosis [7]. Fusarium shows
a dynamic response to opportunities provided by underlying disorders of the host.
Long-Distance Dispersal of Opportunists
Emergence of infectious diseases in humans might be expected to be caused by host shifts from ani-
mal reservoirs to humans [8], as is the case, e.g., in dermatophytes. Fusarium is different. Plant
pathogens are dispersed via direct contact, wind, water, vectors such as insects, or the germline of
contaminated seeds [9]. Host ranges can be broad or narrow; some species seem to be host-specific
(e.g., Fusarium ficicrescens on figs), while others are found on widely different hosts (e.g., Fusarium
oxysporum). Some species are associated with specific geographic areas (e.g., Fusarium lactis in Cal-
ifornia), but most fusaria are ubiquitous [10]. It is possible that outbreaks leading to repeated isola-
tion from the same host plant masquerades as host-specificity; for most species, plant inoculation
experiments have not been done and ecological specialization has not been proven.
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The genus Fusarium was first described in the early 19th century. In 1935, Wollenweber
and Reinking used morphological differences to organize the genus into 16 sections with 65
species, 55 varieties, and 22 forms [11], but later Booth simplified this to only 14 species [12].
When Leslie and Summerell used morphological and phylogenetic information, they ended up
with 70 species, most of which formed falcate, multiseptate macroconidia with a beaked apex
and a pedicellate basal cell. The microconidia are one- to two-celled and pyriform, fusiform, or
ovoid in shape. Both macro and microconidia are produced in the aerial mycelium on phialides
[13]. At present, with the dawn of molecular sequencing, more than 200 species are recognized
in 22 species complexes, differing by morphology, host association, and molecular parameters
[14]. Currently, 74 taxonomic species have been suggested to cause human infections (Fig 1)
[15], judging from their isolation from clinical samples, and this number is expanding. To date,
about 36 of the alleged human opportunists carry a name, while 38 are still unnamed and can
only be identified by multilocus sequence analysis (MLSA). Thus far, 21 species have been
described with proven case reports [16], and more have been published in the literature.
The most common route of human infection is by inoculation via contaminated thorns or
plant leaves, which particularly affects farmers and agricultural workers. However, Fusarium
poses a challenge for human disease management because propagules may disperse over long
distances in the atmosphere, and new resources and susceptible hosts are quickly found [17].
Smith et al. [18] noted that Fusarium conidia are waterborne and become airborne when dried.
Schmale et al. [19] showed that large-scale atmospheric features known as Lagrangian coherent
structures (LCSs) enhance transport of Fusarium in the lower atmosphere. Lin et al. [20] dem-
onstrated that atmospheric populations of fusaria are mixed and that conidial counts do not
vary across consecutive sampling intervals, demonstrating constant airborne transport.
One of the major risk factors for compromised hosts is inhalation of contaminated air. Mor-
etti et al. [21] established a link between Fusarium in the air and in the blood of infected
patients, and suggested unfiltered hospital air may be problematic for these patients. Short
et al. [22] investigated hospital plumbing systems for the occurrence of fungi and found that
these systems are a hidden reservoir for Fusarium. Prevalence of Fusarium species in compro-
mised patient populations is not proportional to their environmental abundance [23], suggest-
ing that infection is not merely a random process.
Prevalence of Fusarium Antifungal Resistance
Fusarium species are intrinsically resistant to azole antifungals. Five azole fungicides are widely
used for plant protection: propiconazole, bromuconazole, epoxiconazole, difenoconazole, and
tebuconazole. Azoles are generally inexpensive and have broad-spectrum activity and long sta-
bility. Azoles that are used clinically have derivatives such as imidazole or triazole rings [24].
The azoles used in agriculture are different, but all azoles target the same active site, i.e., lanos-
terol-14α-demethylase [25]. Effects on Fusarium population dynamics in agricultural fields are
likely due to decreased competition with susceptible species [26]. This may be reinforced by
antifungal prophylaxis in high-risk patients in clinical settings, enhancing selective pressure
that favours multidrug-resistant fungi, including Fusarium [27]. Population dynamic effects
have not been seen before because Fusarium was not considered to be a matter of concern [28].
The growing incidence of severe human Fusarium infections may change this situation.
Multiresistance Against Different Classes of Antifungals
Clinically relevant members of Fusarium are resistant to almost all currently used antifungals
—not only azoles, but also echinocandins and polyenes. This poses a major challenge to medi-
cine and agriculture, particularly with emerging and globally spreading fungi like Fusarium.
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There are only a few options left for treating patients and crops. Intrinsic, primary resistance is
found naturally among some Fusarium species without prior exposure to the drug [29]. Sec-
ondary resistance to azoles develops among previously susceptible strains after exposure to the
antifungal agent, as seen, e.g., in Aspergillus fumigatus, and is usually dependent on altered
expression of CYP51, the gene encoding sterol 14α-demethylase [30]. Recently, Fan et al.
showed that CYP51 in Fusarium has three paralogues (CYP51A, -B, and -C), with CYP51C
being unique to the genus [31]. CYP51A deletion usually causes secondary resistance in fungi
such as A. fumigatus [25], whereas the opposite was found in Fusarium: CYP51A deletion
increases the sensitivity of Fusarium graminearum to azoles and other fungicides (prochloraz,
tebuconazole, and epoxiconazole) that are used in plant protection [31]. The exact resistance
mechanisms in Fusarium are not entirely understood, but combinations of CYP51A amino
acid alterations and/or CYP51A gene overexpression might be involved.
Recent findings indicate that a mutation occurring in the FKS1 gene might contribute to the
intrinsic echinocandin resistance in Fusarium. In support of this, evidence has been presented
that hot spot 1 substitution P647A and F639Y in FKS1 contribute to resistance of Fusarium
solani [32]. Furthermore, Fusarium has an effective efflux mechanism to remove xenobiotics
from its cells [33], and this may also reduce azole sensitivity. Amphotericin B, second-genera-
tion broad spectrum triazoles (fluconazole, itraconazole, voriconazole, and posaconazole), anti-
metabolites (5-fluorocytosine), and echinocandins (caspofungin, anidulafungin, and
micafungin) all have limited activity against Fusarium species. High-level cross-resistance to
fluconazole and itraconazole was reported in almost all Fusarium species. Cross-resistance has
been observed among the three echinocandins in Fusarium species (Fig 2). In vitro data
showed that there is potential for azole cross-resistance to echinocandins and polyenes, but no
clinical information on this phenomenon is available.
Management of Fusarium Infections: New Drugs or Drug
Combinations?
Treatment of fusariosis is a major challenge. For disseminated fusariosis in immunocompro-
mised patients, the 12-week survival time has increased significantly in the last decade in single
center studies [34], national studies, [35] and worldwide evaluations [36]. This better outcome
of treatment is probably associated with the introduction of voriconazole in 2002. Therapy
with amphotericin B deoxycholate gives poor survival results of 28% when compared to lipid
amphotericin B (53%) or voriconazole (60%) [36]. Recent European guidelines [37] suggest
treating disseminated fusariosis with voriconazole and lipid amphotericin B, although evidence
is based on expert opinion and case series rather than on clinical trials. Of the azoles, only the
new triazoles, voriconazole and posaconazole, show moderate activity, with mode minimal
inhibitory concentrations (MICs) of 2–8 mg/L and 0.5–8 mg/L, respectively, depending on the
species complex. The mode MIC of amphotericin B is 2 mg/L irrespective of the species com-
plex (Fig 2) [38]. The newest class of antifungal drugs, the echinocandins, have activity against
Candida and Aspergillus species [30], but for Fusarium they appear to be inactive with high
MICs of>16 mg/L (Fig 2). Terbinafine is another option to treat some Fusarium species, but
this compound is only registered to treatment of superficial infections [39]. Natamycin (5%)
and/or topical amphotericin B (0.5%) are first-line treatment of fungal keratitis in some coun-
tries. Elsewhere, topical 1% voriconazole and/or 5% natamycin are used for this type of infec-
tion [40].
Fig 1. Schematic representation illustrating up-to-date clinical Fusarium species reported from clinical cases and belonging to ten Fusarium
species complexes.
doi:10.1371/journal.ppat.1005464.g001
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Considering the poor outcome obtained with monotherapy, attempts have been made to
determine whether combinations of drugs lead to improved efficacy. Spader et al. [41] reported
that synergistic interactions were observed for the combinations of amphotericin B with caspo-
fungin (68.7%), amphotericin B with rifampin (68.7%), amphotericin B with 5-flucytosine
(59.3%), and amphotericin B with voriconazole (37.5%). Al-Hatmi et al. [42] determined in
vitro antifungal activity of natamycin alone and in combination with voriconazole for Fusar-
ium keratitis, and found that MICs of these compounds alone were>4 and 4−8 mg/L, respec-
tively, and that the combinations tested displayed (70%) in vitro synergistic effects against a
significant number of isolates. MICs values were reduced to 0.02−0.5 mg/L and to 0.13−2 mg/L
in combination, respectively [42]. Combinations of voriconazole, amphotericin B, and posaco-
nazole showed poor efficacy in experimental murine infections by F. verticillioides, while the
combination of liposomal amphotericin B and terbinafine showed good results [23]. However,
clinical studies have not been performed, and the most efficacious combination remains to be
explored. Further work on interactions in animal models or clinical trials with the aim to
obtain higher cure rates of Fusarium infections is overdue.
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